Implanet SA (IM11) Price & Analysis

― Followers

IM11 Stock Chart & Stats

€0.28

>-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.28

>-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.15 - €0.42

Previous CloseN/A

Volume0.00

Average Volume (3M)4.40K

Market Cap

€23.21M

Enterprise Value€28.91

Total Cash (Recent Filing)€3.01M

Total Debt (Recent Filing)€5.92M

Price to Earnings (P/E)―

Beta-0.26

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding143,818,970

10 Day Avg. Volume3,845

30 Day Avg. Volume4,401

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)70.59

Price to Sales (P/S)2.29

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained top-line growth over multiple years indicates rising adoption of Implanet’s implant systems and likely expanded procedure volume or geographic traction. Durable revenue expansion supports scale, helps absorb fixed costs, and creates a pathway to operating leverage if margins and SG&A remain controlled.

Improving Gross MarginA substantial margin expansion suggests positive shifts in product mix, pricing power, or manufacturing efficiency. Higher gross margins are a structural advantage for durable profitability, increasing the potential that incremental revenue translates into meaningful earnings improvement as SG&A growth is managed.

Cash Flow Trend ImprovementProgress toward less negative operating cash flow indicates improving operational discipline and working capital management. While still negative, this trend reduces ongoing funding pressure and, if continued, can form a durable base for self-funded growth and lower reliance on dilutive financing.

Bears Say

Persistent LossesOngoing net losses and negative margins (net margin ~-35% in 2025) mean the business consumes capital rather than generates it. Over months this erodes internal reserves, forces management to prioritize survival/cost cuts over strategic investment, and delays or jeopardizes a sustained shift to profitability.

High Leverage And Thin EquityAn elevated debt load versus a minimal equity base materially limits financial flexibility. With little cushion, the company is vulnerable to covenant pressure, refinancing risk, and limited capacity to fund R&D or commercial expansion without raising costly external capital, constraining strategic options.

Negative Free Cash Flow / Funding ReliancePersistent negative free cash flow implies ongoing need for external financing. Reliance on capital raises or debt introduces dilution, higher financing costs, and execution risk—especially if market conditions tighten—potentially impeding long-term investments and the firm’s ability to scale profitably.

IM11 FAQ

What was Implanet SA’s price range in the past 12 months?

Implanet SA lowest stock price was €0.15 and its highest was €0.42 in the past 12 months.

What is Implanet SA’s market cap?

Implanet SA’s market cap is €23.21M.

When is Implanet SA’s upcoming earnings report date?

Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 43 days.

How were Implanet SA’s earnings last quarter?

Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Implanet SA overvalued?

According to Wall Street analysts Implanet SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Implanet SA pay dividends?

Implanet SA does not currently pay dividends.

What is Implanet SA’s EPS estimate?

Implanet SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Implanet SA have?

Implanet SA has 143,818,970 shares outstanding.

What happened to Implanet SA’s price movement after its last earnings report?

Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.723%.

Which hedge fund is a major shareholder of Implanet SA?

Currently, no hedge funds are holding shares in DE:IM11

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Implanet SA

Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.